Home / Poster / Application of a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for prediction of drug-drug interactions (DDIs) involving the JAK1/2 inhibitor Ruxolitinib in Caucasians and Japanese

ポスター

Application of a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for prediction of drug-drug interactions (DDIs) involving the JAK1/2 inhibitor Ruxolitinib in Caucasians and Japanese

How Model-informed drug development rescue projects from a risky situation

事例紹介

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

ブログ

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

オンデマンド・ウェビナー

【サターラSimcyp PBBMオンライン講座】～PBBMを一から学ぶ～第2回薬物吸収モデルとは？

ウェビナー

Powered by Translations.com GlobalLink Web Software

Application of a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for prediction of drug-drug interactions (DDIs) involving the JAK1/2 inhibitor Ruxolitinib in Caucasians and Japanese

Application of a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for prediction of drug-drug interactions (DDIs) involving the JAK1/2 inhibitor Ruxolitinib in Caucasians and Japanese

How Model-informed drug development rescue projects from a risky situation

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

【サターラSimcyp PBBMオンライン講座】～PBBMを一から学ぶ～第2回薬物吸収モデルとは？

メルマガ登録

クイックアクセス

ソリューション

お問合せ

Application of a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for prediction of drug-drug interactions (DDIs) involving the JAK1/2 inhibitor Ruxolitinib in Caucasians and Japanese

How Model-informed drug development rescue projects from a risky situation​

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

【サターラSimcyp PBBMオンライン講座】～PBBMを一から学ぶ～ 第2回薬物吸収モデルとは？

メルマガ登録

クイックアクセス

ソリューション

お問合せ

How Model-informed drug development rescue projects from a risky situation

【サターラSimcyp PBBMオンライン講座】～PBBMを一から学ぶ～第2回薬物吸収モデルとは？